[go: up one dir, main page]

AR067905A1 - Vacunas - Google Patents

Vacunas

Info

Publication number
AR067905A1
AR067905A1 ARP080103497A ARP080103497A AR067905A1 AR 067905 A1 AR067905 A1 AR 067905A1 AR P080103497 A ARP080103497 A AR P080103497A AR P080103497 A ARP080103497 A AR P080103497A AR 067905 A1 AR067905 A1 AR 067905A1
Authority
AR
Argentina
Prior art keywords
use according
antigen
protein
adjuvant
lsa
Prior art date
Application number
ARP080103497A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39870250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067905(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR067905A1 publication Critical patent/AR067905A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de un antígeno derivado de la proteína circumesporozoíto (CS) de Plasmodium falciparum que se expresa en la etapa preeritrocítica de la infeccion por malaria combinado con un adyuvante farmacéuticamente aceptable, en la fabricacion de un medicamento para vacunar bebés contra la malaria. Reivindicacion 3: El uso de acuerdo con una cualquiera de las reivindicaciones 1 o 2, en el que la formulacion de antígeno y adyuvante comprende además antígeno se selecciona a partir del grupo constituido por CS, LSA-1, LSA-3, AMA-1, MSP-1, TRAP, Exp-1 o un fragmento inmunogeno del mismo. Reivindicacion 4: El uso de acuerdo con una cualquiera de las reivindicaciones 1 a 4, en el que el antígeno CS está fusionado al antígeno superficial de la hepatitis B (HBsAg). Reivindicacion 5: El uso de acuerdo con una cualquiera de las reivindicaciones 1 a 4, en el que la proteína CS o fragmento está en forma de una proteína híbrida que comprende sustancialmente toda la porcion del extremo C de la proteína CS de Plasmodium, cuatro o más repeticiones en tándem de la region inmunodominante de la proteína CS, y el antígeno superficial de la hepatitis B (HBsAg). Reivindicacion 12: El uso de acuerdo con la reivindicacion 11, en el que el adyuvante comprende 3D-MPL, QS21 o una combinacion de 3D-MPL y QS21. Reivindicacion 13: El uso de acuerdo con la reivindicacion 12, en el que el adyuvante comprende además una emulsion de aceite en agua. Reivindicacion 14: El uso de acuerdo con la reivindicacion 12, en el que el adyuvante comprende además liposomas.
ARP080103497A 2007-08-13 2008-08-11 Vacunas AR067905A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95544507P 2007-08-13 2007-08-13
US95733807P 2007-08-22 2007-08-22
US98280107P 2007-10-26 2007-10-26

Publications (1)

Publication Number Publication Date
AR067905A1 true AR067905A1 (es) 2009-10-28

Family

ID=39870250

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103497A AR067905A1 (es) 2007-08-13 2008-08-11 Vacunas

Country Status (21)

Country Link
US (1) US9066899B2 (es)
EP (1) EP2190470B1 (es)
JP (1) JP5508266B2 (es)
KR (1) KR20100068390A (es)
AP (1) AP2010005166A0 (es)
AR (1) AR067905A1 (es)
AU (1) AU2008288508B2 (es)
BR (1) BRPI0815199A2 (es)
CA (1) CA2695477A1 (es)
CL (1) CL2008002361A1 (es)
CR (1) CR11307A (es)
DO (1) DOP2010000056A (es)
ES (1) ES2658347T3 (es)
MA (1) MA31693B1 (es)
MX (1) MX2010001752A (es)
NZ (1) NZ583150A (es)
TR (1) TR201802221T4 (es)
TW (1) TW200924791A (es)
UY (1) UY31285A1 (es)
WO (1) WO2009021931A1 (es)
ZA (1) ZA201001029B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5508266B2 (ja) 2007-08-13 2014-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
CN102458427B (zh) * 2009-05-05 2016-02-03 卡迪拉保健有限公司 麻疹-疟疾联合疫苗
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
CA3002946C (en) * 2009-11-05 2021-11-02 The United States Of America As Represented By The Secretary Of The Navy Plasmodium falciparum sporozoite and liver stage antigens
DK2385107T3 (en) * 2010-05-03 2016-12-12 Pasteur Institut Lentiviral vector-based immunological compounds against malaria
WO2012047679A2 (en) * 2010-09-27 2012-04-12 The Trustees Of The University Of Pennsylvania Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
CN102268093B (zh) * 2011-06-27 2013-06-26 广东药学院 一种肝靶向肽与人干扰素a2b融合蛋白及其制备方法和应用
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
GB201416773D0 (en) * 2014-09-23 2014-11-05 Glaxosmithkline Biolog S A And Chancellor Masters And Scolars Of The The University Of Oxford Novel Methods For Including An Imune Response
WO2016184784A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1
JP2022526334A (ja) 2019-03-25 2022-05-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新たなタウ種を標的化することによるタウオパチー障害の処置の方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
EP0071705B1 (en) 1981-05-21 1989-11-23 The Wellcome Foundation Limited Protozoal antigen
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
GB9002512D0 (en) 1990-02-05 1990-04-04 3I Res Expl Ltd Polypeptides and dna encoding same
GB9012580D0 (en) 1990-06-06 1990-07-25 Univ Nijmegen Novel protein
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5198535A (en) 1991-01-10 1993-03-30 The United States Of America As Represented By The Secretary Of The Navy Protective malaria sporozoite surface protein immunogen and gene
ES2129461T3 (es) 1991-11-16 1999-06-16 Smithkline Beecham Biolog Proteina hibrida entre cs de plasmodium y hbsag.
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
CZ289476B6 (cs) 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AU6524698A (en) 1997-03-29 1998-10-22 Ji Hoon Park Continuous injecting apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
DE69840962D1 (de) 1997-08-29 2009-08-20 Antigenics Inc Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
WO2002077195A2 (en) 2001-03-26 2002-10-03 Walter Reed Army Institute Of Research Plasmodium falciparum ama-1 protein and uses thereof
AU2002360429A1 (en) 2001-11-26 2003-06-10 Avigen, Inc. Methods for producing stocks of recombinant aav virions
JP5404990B2 (ja) 2002-10-23 2014-02-05 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム マラリアに対するワクチン接種の方法
US7550275B2 (en) 2002-11-12 2009-06-23 The United States Of America As Represented By The Secretary Of The Navy Expression, purification and uses of a Plasmodium falciparum liver stage antigen 1 polypeptide
GB0420634D0 (en) 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
EP1802336B1 (en) 2004-10-14 2011-09-07 Crucell Holland B.V. Malaria prime/boost vaccines
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP1754717A1 (en) 2005-08-19 2007-02-21 Université de Lausanne Antigenic peptides and their use
JP5508266B2 (ja) 2007-08-13 2014-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US9821046B2 (en) * 2013-01-21 2017-11-21 Oxford University Innovation Limited Composition and uses thereof

Also Published As

Publication number Publication date
US20110212159A1 (en) 2011-09-01
ZA201001029B (en) 2011-04-28
AP2010005166A0 (en) 2010-02-28
CL2008002361A1 (es) 2009-08-07
CR11307A (es) 2010-05-24
CA2695477A1 (en) 2009-02-19
UY31285A1 (es) 2009-03-31
TW200924791A (en) 2009-06-16
JP5508266B2 (ja) 2014-05-28
ES2658347T3 (es) 2018-03-09
TR201802221T4 (tr) 2018-03-21
AU2008288508A1 (en) 2009-02-19
JP2010535836A (ja) 2010-11-25
AU2008288508B2 (en) 2014-05-01
DOP2010000056A (es) 2010-07-31
MA31693B1 (fr) 2010-09-01
EP2190470B1 (en) 2017-12-13
CN101820901A (zh) 2010-09-01
US9066899B2 (en) 2015-06-30
NZ583150A (en) 2012-05-25
BRPI0815199A2 (pt) 2015-03-31
WO2009021931A1 (en) 2009-02-19
EP2190470A1 (en) 2010-06-02
MX2010001752A (es) 2010-03-10
KR20100068390A (ko) 2010-06-23

Similar Documents

Publication Publication Date Title
AR067905A1 (es) Vacunas
ES2529577T3 (es) Vacunas contra la malaria
Lee et al. Recent advances of vaccine adjuvants for infectious diseases
Cohen et al. From the circumsporozoite protein to the RTS, S/AS candidate vaccine
Moser et al. Influenza virosomes as a vaccine adjuvant and carrier system
Hill Pre-erythrocytic malaria vaccines: towards greater efficacy
Salvador et al. An overview on the field of micro‐and nanotechnologies for synthetic peptide‐based vaccines
Mata et al. Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research
HRP20110786T1 (hr) Inicijalno i pojačivačko cjepivo protiv malarije
PE97298A1 (es) Composicion para vacunas
WO2010040000A3 (en) A multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia
AR061894A1 (es) Vacunas para malaria
AR051023A1 (es) Vacunas que contienen antigeno de plasmodium
Pearson et al. Induction of CD8+ T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine
Parodi et al. Inactivated influenza vaccines: recent progress and implications for the elderly
Ssemaganda et al. Induction of Plasmodium-specific immune responses using liposome-based vaccines
US20180028635A1 (en) Composition and uses thereof
Kaur et al. Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review
Miyata et al. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine
UY31510A1 (es) Vacunacontra la malaria, especifica para el parasito plasmodium falciparum
AR038311A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
DK1697405T3 (da) LSA-5 leverstadium- og blodstadium-antigen fra Plasmodium falciparum, immunogent præparat omfattende dette antigen samt vacciner mod malaria
Frevert et al. Arrest in the liver-A genetically defined malaria vaccine?
WO2018015815A3 (en) Plasmodium with histamine releasing factor (hrf) deficiency for use as a vaccine
ZHANG he world’s first malaria vaccine: Hope and challenge

Legal Events

Date Code Title Description
FA Abandonment or withdrawal